Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR

Qiumei Yao; Yinlei Bai; Shaji Kumar; Elaine Au; Alberto Orfao; Chor Sang Chim

doi:10.3389/fonc.2020.611021

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR

Qiumei Yao, Yinlei Bai, Shaji Kumar, Elaine Au, Alberto Orfao, Chor Sang Chim

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were identical in 33/35 (94%). Sensitivity of 10⁻⁵ was confirmed in 28/29 (96%) by NGS while sensitivity of RQ-PCR was 10⁻⁵ in 7 (24%), 5 × 10⁻⁵ in 15 (52%), and 10⁻⁴ in 7 (24%). Among 14 samples quantifiable by ASO RQ-PCR, NGS yielded comparable results in 12 (86%). Applicability of NGS can be improved if immunoglobulin heavy-chain incomplete DJ primers are included.

Original language	English (US)
Article number	611021
Journal	Frontiers in Oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.611021
State	Published - Jan 29 2021

Keywords

allele-specific oligonucleotide real-time quantitative-PCR
minimal residual disease
multiple myeloma
next-generation sequencing
sensitivity

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2020.611021

Cite this

@article{130d9f8113da4766aaa91d26eb3eb098,

title = "Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR",

abstract = "Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were identical in 33/35 (94%). Sensitivity of 10−5 was confirmed in 28/29 (96%) by NGS while sensitivity of RQ-PCR was 10−5 in 7 (24%), 5 × 10−5 in 15 (52%), and 10−4 in 7 (24%). Among 14 samples quantifiable by ASO RQ-PCR, NGS yielded comparable results in 12 (86%). Applicability of NGS can be improved if immunoglobulin heavy-chain incomplete DJ primers are included.",

keywords = "allele-specific oligonucleotide real-time quantitative-PCR, minimal residual disease, multiple myeloma, next-generation sequencing, sensitivity",

author = "Qiumei Yao and Yinlei Bai and Shaji Kumar and Elaine Au and Alberto Orfao and Chim, {Chor Sang}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Yao, Bai, Kumar, Au, Orfao and Chim.",

year = "2021",

month = jan,

day = "29",

doi = "10.3389/fonc.2020.611021",

language = "English (US)",

volume = "10",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

T2 - A Comparison With Real-Time Quantitative PCR

AU - Yao, Qiumei

AU - Bai, Yinlei

AU - Kumar, Shaji

AU - Au, Elaine

AU - Orfao, Alberto

AU - Chim, Chor Sang

PY - 2021/1/29

Y1 - 2021/1/29

N2 - Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were identical in 33/35 (94%). Sensitivity of 10−5 was confirmed in 28/29 (96%) by NGS while sensitivity of RQ-PCR was 10−5 in 7 (24%), 5 × 10−5 in 15 (52%), and 10−4 in 7 (24%). Among 14 samples quantifiable by ASO RQ-PCR, NGS yielded comparable results in 12 (86%). Applicability of NGS can be improved if immunoglobulin heavy-chain incomplete DJ primers are included.

AB - Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were identical in 33/35 (94%). Sensitivity of 10−5 was confirmed in 28/29 (96%) by NGS while sensitivity of RQ-PCR was 10−5 in 7 (24%), 5 × 10−5 in 15 (52%), and 10−4 in 7 (24%). Among 14 samples quantifiable by ASO RQ-PCR, NGS yielded comparable results in 12 (86%). Applicability of NGS can be improved if immunoglobulin heavy-chain incomplete DJ primers are included.

KW - allele-specific oligonucleotide real-time quantitative-PCR

KW - minimal residual disease

KW - multiple myeloma

KW - next-generation sequencing

KW - sensitivity

UR - http://www.scopus.com/inward/record.url?scp=85101028351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101028351&partnerID=8YFLogxK

U2 - 10.3389/fonc.2020.611021

DO - 10.3389/fonc.2020.611021

M3 - Article

AN - SCOPUS:85101028351

SN - 2234-943X

VL - 10

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 611021

ER -

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this